Skip to main content
Top

Open Access 17-06-2024 | Fatty Liver | Special supplement : MAFLD

MAFLD: from a disease framework to patient care

Authors: Mohammed Eslam, Jacob George

Published in: Hepatology International

Login to get access

Excerpt

The year 2020 marked a watershed for Hepatology with an international panel suggesting a radical framework for the diagnosis of people with fatty liver disease related to metabolic dysfunction. The panel headed by experts from the Asia Pacific led to the introduction of the term metabolic dysfunction-associated fatty liver disease (MAFLD) and a novel diagnostic classification [1, 2]. The latter divided patients with MAFLD into three relatively homogenous groups—those who had steatosis and were overweight or obese according to ethnic-specific BMI criteria, those who had type 2 diabetes, and those who were of healthy weight but had two or more specified metabolic risk criteria (Figure 1). Subsequently, in the same year, APASL published the first global consensus guidelines on MAFLD [3], which was rapidly followed by guidelines from other national and pan-national societies and patient groups [47]. Since MAFLD can occur at any stage of the life span, a pediatric definition was introduced with age-appropriate criteria [8].
Literature
1.
go back to reference Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209CrossRefPubMed Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209CrossRefPubMed
2.
go back to reference Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1CrossRefPubMed Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1CrossRefPubMed
3.
go back to reference Eslam M, Sarin SK, Wong VW-S, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919CrossRefPubMed Eslam M, Sarin SK, Wong VW-S, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919CrossRefPubMed
4.
go back to reference Fouad Y, Esmat G, Elwakil R, et al. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc. 2022;28(1):3CrossRef Fouad Y, Esmat G, Elwakil R, et al. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc. 2022;28(1):3CrossRef
6.
go back to reference Gorczyca-Głowacka I, Wełnicki M, Mamcarz A, et al. Metabolic associated fatty liver disease and cardiovascular risk: the expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiologia Polska (Polish Heart Journal). 2023;81(2):207–214CrossRefPubMed Gorczyca-Głowacka I, Wełnicki M, Mamcarz A, et al. Metabolic associated fatty liver disease and cardiovascular risk: the expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiologia Polska (Polish Heart Journal). 2023;81(2):207–214CrossRefPubMed
8.
go back to reference Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864–873CrossRefPubMed Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864–873CrossRefPubMed
9.
go back to reference Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260CrossRefPubMed Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260CrossRefPubMed
10.
go back to reference Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150CrossRefPubMed Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150CrossRefPubMed
11.
go back to reference Fouad Y, Lazarus JV, Negro F, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53(10):1080–1089CrossRefPubMed Fouad Y, Lazarus JV, Negro F, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53(10):1080–1089CrossRefPubMed
12.
go back to reference Al-Omary A, Byth K, Weltman M, George J, Eslam M. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. J Dig Dis. 2022;23(1):33–43CrossRefPubMed Al-Omary A, Byth K, Weltman M, George J, Eslam M. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. J Dig Dis. 2022;23(1):33–43CrossRefPubMed
13.
go back to reference Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651CrossRefPubMed Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651CrossRefPubMed
14.
go back to reference Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700CrossRefPubMed Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700CrossRefPubMed
15.
go back to reference Eslam M, George J. Two years on, a perspective on MAFLD. eGastroenterology. 2023;1(2):100019CrossRef Eslam M, George J. Two years on, a perspective on MAFLD. eGastroenterology. 2023;1(2):100019CrossRef
16.
go back to reference Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(8):1831–415.e5CrossRefPubMed Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(8):1831–415.e5CrossRefPubMed
19.
go back to reference Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021;6(1):73–79CrossRefPubMed Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021;6(1):73–79CrossRefPubMed
21.
go back to reference Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–3030CrossRefPubMed Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–3030CrossRefPubMed
22.
go back to reference Fukunaga S, Nakano D, Kawaguchi T, et al. Non-obese MAFLD is associated with colorectal adenoma in health check examinees: a multicenter retrospective study. Int J Mol Sci. 2021;22(11):5462CrossRefPubMedPubMedCentral Fukunaga S, Nakano D, Kawaguchi T, et al. Non-obese MAFLD is associated with colorectal adenoma in health check examinees: a multicenter retrospective study. Int J Mol Sci. 2021;22(11):5462CrossRefPubMedPubMedCentral
23.
go back to reference Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatol. 2002;35(2):373–379CrossRef Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatol. 2002;35(2):373–379CrossRef
Metadata
Title
MAFLD: from a disease framework to patient care
Authors
Mohammed Eslam
Jacob George
Publication date
17-06-2024
Publisher
Springer India
Keyword
Fatty Liver
Published in
Hepatology International
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-024-10685-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare